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Com puter Science

A General and Age-dependent Physiological Based Pharmacokinetic (PBPK) Model
Development

Chairperson: Dr. Jesse John
Physiologically-based pharmacokinetic modeling (PBPK) is a mathematical modeling
technique for assessment of human heath risks and investigation o f the toxicity. It can
predict the target tissue dose concentration and their metabolites at target tissues. The
currently available pharmacokinetic (PK) and pharmacodynamic (PD) data for dosing
recommendations in patients are limited. In addition, the absorption and metabolism of
drugs for the patients are extremely variable, and the inter-individual variability depends
on age, race, and gender. Many PBPK models have been developed, but m ost of them are
commercialized. Free PBPK models usually lack usability and flexibility, e.g., they
require additional software support. To guide drugs dosing in various patient populations,
a general and age-dependent PBPK model has been constructed to systematically study
drugs metabolism and pharmacokinetics. This model includes whole-body multi-organ
distributions, plasma protein binding, metabolism, and a scaling module.
Parameterization of this module is based on a database of PK parameters and data
collected from clinical experiments. The new PBPK model also has a user interface
which is easy to learn and to use. It also provides the customization flexibility for doctors
and researchers, such as organ selections, and communication flexibility, i.e., the XM L
storage o f drugs and the patient information, and the human body setting standards.
Results o f experimentation show the model can be adapted to explore more general
situations such as multiple dosage and other drugs.
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SECTION 1: INTRODUCTION
1.1 Background
Physiologically-based pharm acokinetic modeling (PBPK) is a mathematical
modeling technique for assessing human health risk and investigating drugs toxicity. It
can predict the target tissue dose concentration and their metabolites at target tissues.
Also, it is a valuable tool for drug development and approval, risk assessment and
research in many areas. PBPK is not a new concept; it can be traced back to the 1920s.
Teorell [1] was the first person to describe the concepts o f a PBPK model. Because
PBPK modeling involves complex mathematical computation, including differential
equation solving, it is hard to implement the PBPK model by hand calculation. In the
1970s, Bischoff [2] and Brown [3] utilized computer to implement the first PBPK model
which was applied for anticancer drugs. W ith the computer technology support, PBPK
modeling has been applied in environmental assessment. Likewise, M apleson and
colleagues in Cardiff developed PBPK models for anesthetic agents [4], One important
application of PBPK modeling is to predict the pharmacokinetics o f a drug in humans
based on animal data. M ost of PBPK models have common characteristics. The PBPK
model consists of physiological parameters, drug specific parameters, and the model
structure components. Physiological parameters are defined by; organ size, blood flow,
composition and functionality. Physiological parameters are independent o f the drug.
Drug specific parameters include protein binding, tissue affinity (partition coefficients),
membrane permeability, and enzymatic activity.
The drug enters the organs from the arterial blood and returns to the heart in the
venous blood. Elimination occurs in specific organs, such as kidney and liver. It is
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com monly assumed, at least for lipophilic drugs, that the uptake of drug by the tissue is
blood-flow limited. Mass balance equations are written for each organ, and described by
a series o f differential equations.
Currently, many PBPK models have been developed. The summary o f the current
PBPK software is listed in appendix Table 1.

1.2 Problem Statem ent
The currently available pharmacokinetic (PK) and pharmacodynamic (PD) data for
dosing recommendations in patients are limited. In addition, the absorption and the
metabolism o f drugs for the patients are extremely variable. The inter-individual
variability depends on age, race, and gender. Many PBPK models have been developed,
but most of them are commercialized (see the summary in appendix Table 1). Other free
PBPK models lack usability and flexibility (e.g., requiring additional softweire support).
To guide the dose administration and research, it is important to build a free and flexible
PBPK model.

1.3 Motivation
The motivation to build a PBPK model was from my internship at the Medical
College of W isconsin in the summer o f 2005. As a member of the PBPK model
development team, I participated in the coding work. The purpose o f that PBPK model
was to predict the concentration of methadone in a child’s body. Since methadone was
mostly metabolized in the liver (by enzyme CYP3A4), the metabolism model was fixed
in the liver. The PBPK model functioned well, but was highly coupled to functions, and

too specific. It will be hard to reuse and extend. It would be interesting to build a flexible
PBPK model by separating the mixed modules into individual modules with a less
coupling, and each module only will do on one specific function. Further, it will be
helpful to gain experience by applying the software design knowledge to biological
computations. Storing the parameters in several XM L formatted files, provides a solution
to the platform-dependency problem. The main purpose of this project is to create an agedependent, race and gender PBPK model, which can be used by both doctors and
researchers.

1.4 Goal
The first goal is that this model can guide drug dosing in various patient
populations. The second goal is the correctness of this new PBPK model. The third goal
is to have a friendly user interface and being easy to leam and to use. The fourth goal is
to provide customization flexibility, such as organ selections, and com munication
flexibility (i.e., the XM L storage of the drug and the patient information, and human body
setting standards). The final goal is to include computational efficiency for rapid
feedback.

1.5 Benefits
PBPK modeling offers considerable efficiency and effectiveness in the drug
development process, reducing both time and money required to bring a successful drug
to market. The PBPK model aims to serve doctors and researchers related to drug or
chemical areas. W ith this PBPK model, they can predict the concentration of drug

distribution more accurately, so doctors are able to give the right prescription for the
individual patient. Researchers can do fewer animal and human studies with the help of
this PBPK model. The use o f PBPK modeling is also beneficial in predicting human
dose-response relationships by using epidemiologic and animal data. Due to the ethical
issues, human dosing studies during lactation are rarely available and are expensive. An
additional benefit is that this PBPK model is a free software and anyone can use it. It
allows users to construct PBPK modeling by simply selecting the important organs. The
model can predict the concentrations for patients of any age.

1.6 Paper Organization
This paper is divided into five sections.
•

“Section 1: Introduction” gives the background o f PBPK, what the PBPK
model is, why I chose this project, what benefits there are, and the goal of
this PBPK model.

•

“Section 2: Modeling Approach and Numerical M ethods” discusses the
principle and structure of the PBPK model. Most of the paragraphs were
spent on describing the math expressions o f sub models integrated into this
PBPK model.

•

“Section 3: PBPK Model Developments” focuses on software engineering
design and implementation. First, it depicts the system requirements,
architecture, data flow, GUI and X M L file design, and a UM L design
diagram. Secondly, it talks about the methods in software engineering and

the core functionalities* implementations including ODE solving, optim izer
setting, and XM L implementing.
“Section 4: Results’*discusses the relationship between the volume and the
age, model validation results, the prediction o f the PBPK model, user
interface and what new features this PBPK model includes.
“Section 5: Conclusion and Future W ork” gives a general summary about
this PBPK model and what future works should be focused on.

SECTION 2: MODELING APPROACH AND NUMERICAL METHODS

2.1 Literature Search Methods and Parameters
Before developing a PBPK model, it is necessary to gain the knowledge about the
PBPK model from research papers. To validate the new PBPK model, the distribution
data o f drug in the hum an body also are important.
•

Literature search
The first literature searches were conducted by searching PubM ed and Google.
Key words were "PBPK, PBPK model development". Another way to search
PubM ed and Google is to search the references listed in the papers. If those
papers are not available in PubM ed or Google, they may be searched through
the libraries o f The Medical College of W isconsin, University o f Madison, and
University o f Montana.

•

Experim ental data collection
Methadone, fentanyl, and nevirapine are selected to validate the PBPK model.
The concentration data and curve of those three drugs were found from the
literature papers. Software “Scanit” was used to read the concentration and the
time from those curves. The pharmacokinetics parameters were also added into
the XML tables.

•

M odel parameters
Two types o f parameters in the PBPK model are the physiological and the
pharmacokinetics parameters. Human physiological parameters are obtained
from literature found by Feng (cardiac output, alveolar ventilation, blood flow

rate, tissue volume, tissue blood flow rate) in appendix Table 7. The
pharmacokinetics parameters refer to the tissue blood partition coefficients,
clearance, protein binding, and drug basic information. These parameters of
Methadone, Fentanyl, and Nevirapine are listed in appendix Tables 8, 9.

2.2 The Principles o f PBPK Model
The conventional PBPK model was developed to describe the pharmacokinetics of
drugs both in blood and various body tissues. The lifecycle o f drug after administration is
determined by the relative rates of absorption, distribution, metabolism, and elimination
(ADME). The general disposition of drugs can be described as follows. Once the drug
enters a vein, it is distributed into the blood circulation. W hen the drug enters the blood* s
circulation, it may become bound to plasma proteins. The protein bound drug is inactive
and cannot distribute to tissues. The drug in the vein will flow into the lungs and then
circulate into artery. Then the total blood will be partitioned into organs or tissues. The
dynamic equilibrium of drugs and organs is determined by the organ’s blood flow rate. If
the drug is a substrate of enzymes in the organ, the metabolism will happen. M etabolites
of drugs will be eliminated out the human body. Normally, this elimination occurs in the
liver and kidney.

2.3 The Structure of PBPK Model
In the human body, there are no obvious boundaries between tissues. M ost tissues
are complex. The conventional PBPK made these assumptions summarized from the
paper [5];

•

Only the large and essential tissues will be used in PBPK.

•

Drug dissolved in each compartment.

•

Each organ is a well-mixed compartment.

•

Drug uniformly distributed.

•

Body represented by series o f tissues.

•

Drug moves in and out o f tissues and is satisfied with the linear ordinary
differential equation and conservation equation.

•

Groups o f tissues have sim ilar blood flow and drug affinity.

•

Protein binding within the tissue happens immediately.

Considering the above assumptions, a PBPK model consisting o f 14 organs or
tissues is chosen. The detail of PBPK structure is shown in Figure 1. Each box
corresponds to a well-mixed compartment and each arrow represents an input or output to
the compartment determined by blood flow. The model incorporates transport processes
and cellular metabolisms in major tissue-organ systems involved in the drug metabolism,
distribution, and clearance. The rate of change in the amoimt of drug can be described as
a mass balance differential equation.

2.4 The M odel s Num erical Expression
To describe and predict the distribution of drug in the body, many essential sub
models including protein binding, metabolism, transient mass balance, and scaling model
from adult to children are integrated to the new PBPK model. The following section
discusses these sub models in detail.
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2,4,1 Protein Binding M odel
It is generally assumed that only free (unbound) drugs can produce a
pharmacologic effect and protein bound drugs cannot metabolized and filter through the
kidney [6]. Thus, plasma protein binding is an important factor for individual variations
in some drug

M w cl#
S l^

^

S p to m

Adipose
New Organ

others
KM oeÿ
Urine

___________

Liver
IV

Intestine

■jr

Metabolites

Figure 1: The structure o f PBPK model

clearance. Small changes in the binding of highly bound drugs can cause significant
changes in clinical response. Thus the plasma protein binding is a key model component.

Since the binding o f a drug may involve 1 or 2 sites, a model o f binding can be
formulated by accounting for two non-cooperation affinities [7].

B _ n^K^P ^
F
l + K^F l + ATjF

where B is the bound concentration of methadone, F is the free concentration in plasma,
P is the total protein concentration (mol/L),

and K 2 are binding constants (1/ (mol/L))

and Wj and «2 are the numbers of non-competitive binding sites. Then the free fraction
of drug yh is;

F
F +B

I
1+ F / F

1

f u — ------------ — ----------------- — -------------------------------------------

('2,^

^ , fhK^P ^ n^K^P
1+ F ,F I + F 2 F

If the protein binding is not saturated and only the high affinity site is considered, then
AT,F « 1 and

^

l + n^K^P'

In this model, binding constants K^ and Kj are assumed to be constants and all
protein bindings have the similar mathematic expression. Tissue protein binding is
incorporated into a partition coefficient for each organ and/or tissue.
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2AJ2 M etabolism M odel
In drug metabolism, a variety o f enzymes are involved. W e assumed that the drug
metabolism for all enzymes can use the classical M ichaelis-M enten model, which is used
to model the metabolic rate [8],

t

ISFxV,^xfii^xC^
/C‘ + > * x C ‘

’

where the superscript k indexes the /c-th organ in the PBPK model, C* is the total
concentration o f methadone in the metabolizing tissue in organ k (i.e. liver and intestine),
, AT* are M ichaelis-M enten constants, and ISF is the infant scaling factor used to scale
the adults
clearance (

to infants

. Clearly, the metabolic rate depends on /h * , /5F , and intrinsic

/ K* ), which represents the intrinsic enzymatic activity o f the liver.

2,4.3 M ass Balance Equation f o r Each Organ
It is assumed that membrane transport is very rapid and transport flow is limited for
all regions. All organs are modeled as a series o f interconnected continuous stirred tank
reactors. Nearly all organs and tissues are simulated in this PBPK model, including
kidney, brain, GI organs, liver, spleen, muscle, lung, adipose, heart, and skin. Other
organs are included in this model by creating an “Others” organ to group them so that the
scaled whole-body composition reflects the entire individual [5].

Given the assumption of flow limited compartmental transport, transient mass
balances can be written for each o f the body regions considered. Specifically, mass
balance for the pool of blood is expressed as
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where

is total cardiac output,

is the arterial blood concentration of drug.

is the

mixed venous concentration of drug and can be calculated from

k

(6)

^

where Q* ,

and P* are the volumetric blood flow, the concentration, and the partition

coefficient o f the organ A:, respectively. Here, overall partition coefficients which relate
blood and tissue concentrations are used, protein binding in tissue is assumed to be linear.
The mass balance in compartments other than the metabolizing tissues and clearance
tissues is given by:

=

(7)

where V* is the volume o f the specified organ. In these tissues, the disappearance of
drugs is assumed to be diffusion driven and is accounted for in the above mass balance
equation. For metabolizing tissues or clearance tissues (i.e., liver, intestine, or kidney),
mass-balance differential equations are expressed as:

dC^
=
dt

(8)
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where /?* is the metabolic or clearance rate in Xc-th tissue. For metabolizing tissues (i.e.
liver and intestine),

may include more than one independent metabolism term

resulting from different enzymes.

2*4,4 Scaling Factors fo r Age^Dependent Variability
There exist numerous PBPK models developed for a variety of drugs in adults, but
specific PBPK models for children, especially for newborns and infants, are less well
established. In the developmental stages, drug metabolism and disposition are
dramatically different from those in adults. For example, some enzymes are in much
lower levels in children than in adults, and some are even non-existent in neonates. Thus
it is necessary to generate PBPK parameters that are appropriate for children.

Based on archival data and information in the literature, we have assembled a set of
empirical regression functions to account for age-dependent variation in organ volume,
blood flows, plasma protein concentrations, and enzyme activities. In choosing
appropriate regression equations, it is preferable to use direct measurements of tissue
parameters, to include a relatively large numbers o f individuals in the data sets, and to
have relatively high correlations between models and experimental data [9]. Particularly
in this study, preference is given to those equations based directly on the study of infants
and young children, rather than equations based on the adult data alone, which have to be
extrapolated in order to predict the physiological parameters for children. The available
regression equations have been screened and in some cases slightly modified, based on
the results from cross-validations by ICRP (2002, http://www.irpa.net), independent
surveys (NHANES III survey, approximately 33,994 records), IS LI human database and
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data from the literature [10] [11] [12]. In the regression equations, physiological
parameters are usually expressed as a function of age, gender, body weight, and body
height, as shown in appendix Table 2. Partition coefficients, M ichaelis-M enten constants,
and renal clearance are assumed to non age-dependent.
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SECTION 3: PBPK MODEL DEVELOPMENT

3.1 PBPK M odel Design
W hen we determine the structure of the PBPK model, it is wise to consider how to
design the software, which includes all the functionalities described before. To develop
complex PBPK model software, the process of software engineering development
strategy should be complied with. In the following sections, a detailed description of
software engineering is introduced.
3.1 A System Requirements
The system requirements are gathered from the bioengineering computation group
at the BBC group o f Medical College o f W isconsin and the interview with doctors and
students majoring in pharmacy. All requirements are listed from high priority to low
priority:
High priority:
• The PBPK model can predict the distribution o f drug in blood and each essential
organ.
• The PBPK model can simulate the concentration-time curve given the
experimental data.
• Allow users to select organs to construct a flexibility PBPK model structure.
• This model should include protein binding, metabolisms, scaling, infusion and
oral dosing models.
• This model will display the concentration versus time curve for each organ.
• Users can turn the protein binding or metabolism model for each organ on or off.
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• Allow users to prescribe multiple dosages to the patient.
• X M L files store the patient, drug, and standard human parameters.
• This model should include an optimizer to adjust the target parameters by fitting
the experimental curve.
• This model should have an intuitive user interface.
• This model should allow users to save the concentration curves
Low priority:
• A web based user interface allows users to input the information o f the patient
and the drug parameters.
• Include a drug interaction model.
• Optimize several experimental data for a drug.

User

PBPK Model
Data 1/0
Initialize

GUI

D ispla y

Computation

Data Storage
XML Files
Figure 2: The system architecture consists o f three tiers: User tier, PBPK M odel tier,
and XM L Files storage. User tier handles inputting the data and displaying
the data; PBPK M odel will preprocess model parameters and com pute the
concentrations in each organ; XM L Files will be used to store patients data,
drug data, and hum an body setting parameters.
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3A .2 System A rchitectures
From design view, using multiple tiers is a good solution for a complex product,
which intends to be easy to extend and to reuse. The GUI tier (read and display data), the
data controller tier (initialize data), and the core tier (computer data) are used for this new
PBPK model. In consistency of programming language with the computation group at
BBC, we chose M atlab to develop the PBPK model. The system architecture containing 3
tiers is shown in Figure 2.

3.1.3 P B P K M odel D ata F low D esign
The data flow walks through four scenarios. In the first scenario, the user selects
the patient, the drug, and the experimental data, and then the program stores these
parameters into a structure. The second scenario mainly preprocesses reading data,
calculates the human body setting, and scales all parameters o f organs and drugs
depending on the patient age, race, weight and height. In the third scenario, the model
will execute the core functions o f the PBPK model, which calculate the concentration for
each organ by calling the ODE solver. The final scenario displays the concentration
versus time curve for each organ, and also displays the pharmacokinetics o f drugs in the
main window. The detailed design is described in Figure 3.
3.1.4 G U I D esign
GUI design will follow the user interface design strategies, which focus on
usability, good feedback, and error avoiding. The main window style will be similar to
the M icrosoft W indow style. It consists o f four functional areas: “Menu toolbar”, “Begin
PBPK M odel”, “Parameters adjusted block” and “Display patient and drug
pharmacokinetics”. The detail design is as follows.
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r Data Read,
GUI Input
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PBPK Related Data

•

M enu bar
Five menus: File, Patient, Body Setting, Drug Setting, and Help.

•

Begin PBPK M odel Area
“Begin PBPK Model Area” should provide these functions such as selecting a
patient, selecting a drug, giving a prescription, and loading experiment data.

•

Param eters Adjusted Block
It should include the most often adjusted parameters such as the patient (age,
race, weight, and height), the partition coefficient. M etabolism parameters Vm,
Km, optim izer setting, and the detail adjusted for the drug and the body
parameters.

•

Display block
It should display the patient name, the drug name, and the drug
pharmacokinetics. The plasma concentration versus time curves will be shown
on the pop-up window.

3.1.5 X M L F iles D esign
Four XM L files (“patientData.xm l”, “standardData.xml”, “drugParams.xml”,
“controlM odelData.xml”) are designed to store the patient data, the drug data, and the
standard body setting and the control model setting. Each file consists o f a root element
and sub elements. The detailed design can be founded in appendix Tables 3 ,4 , 5, 6.

3.1.6 P B P K M odel M odule U M L D esign
According to the PBPK model data flow design, the UM L diagram has been
designed in Visio UM L tool. Since Matlab is an interpreting language w hich is different
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from Java and C++ (compiling), each function has to be saved as in a M atlab file. The
U M L diagram based on files is designed, and each file in the UM L diagram will only
perform a specific functionality. The UM L design diagram is shown in Figure 4.
3 ,1 .7 M ilestone Setting
Since this project has to be finished by the end o f April, in order to catch the
deadline, nine milestones are set.
•

M ilestone 1: Jan. 23 —Feb. 5, read papers; understand the principles o f PBPK
Model; leam XM L and find a way to parse XM L file into Matlab.

•

M ilestone 2: Feb. 6 —Feb. 15, implement the requirements, system architecture,
PBPK model architecture design, XM L file design, PBPK Model module UM L
design, and GUI Design.

•

M ilestone 3: Feb. 16 - Feb. 20, create the XM L files and know how to read a
XM L file into Matlab.

•

M ilestone 4: Feb. 21 - Mar. 1, implement and test the basic functionalities
including “PBPK_ODE_Solve.m”, “ODE_SET.m”, “main.m”,
“Single_Dose_Solver.m”, ‘Tlot_Curve.m , InitDataStruct.m”.

•

Milestone 5: Mar. 2 —Mar. 8, implement functionalities including
“CalTVector.m”, “M ethadoneExpData.m”, “Optimizer_set.m”,
“PBPK_Optimizer_Solver.m” , “M ulti_Dose_Solver.m”, and
“Optimizer_fiin. m” .

•

M ilestone 6: Mar. 9 —Mar. 16, work on the scaling model coding
(“Scale2Infant.m”), and integration testing.
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•

M ilestone 7: Mar. 17 —April 20, finish writing the paper

•

M ilestone 8: May 1 - May 7, give oral presentation

3.2 Im plem entation
Since M atlab provides a suite of powerful tools in mathematical solutions and is
popular language in computational research, the new PBPK model is implemented in
Matlab. This project follows the evolutionary software development process. First, a
working system with basic functionality was implemented, and then testing began until
the project worked well. Second, more functionalities were added into this project, and
started integrated model testing. The process was iterated until all methods were
implemented. The project adhered to the milestones. GUI was implemented by the
“Guide” tool. All source codes are attached in the appendix.

3,2,1 Softw are E ngineering R u les
During the implementation, I followed these software engineering methods:
•

File creation
The main functionality was created in one file and the file name was the same as
function name. XM L file is named as “xxx.xml” format, and Matlab file is
named as “xxx.m ” format.

•

Commenting
All files will have the same commenting block at the beginning of each file,
which describes the class’s functionality, purpose, and any special notes. In
addition, each function will be commented as to its purpose and each method
implementation will be preceded by a com ment block which describes the
m ethod’s functionality, parameters, and outputs, as well as other information
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described in the C S441/442 Coding and Commenting Standards. Further
comments will be inserted to describe program flow and any other important
aspects o f the code, as being determined by the coder.
•

Coding standard
All codes will adhere to the standards set out in the aforementioned Coding and
Commenting Standards document. All function names are capitalization
conventions, and most variables are low capitalization at the first letter. All
functions are using the indenting and white space.

3,2,2 Core F unctionalities Im plem entation
•

ODE solver implementation
ODE solver includes a single dosage and a multiple dosage sub model. Both

sub models requires an ODE_SET function that computes the differential equation
handles. The differential equations are computed in order by organ, vein->artery>liver->intestine->kidney->brain->lung->muscle->adipose->heart->skin->spleen>new l->others. The infusion of dose was added into a vein directly and the oral
input was added into liver. The multiple-dosage model was implemented by calling
ode23s solver function repeatedly. The repeated times depend on the dosage
interval time and the lasting time. At each repeated time, the concentrations are
passed as the initial parameters.
•

Optim izer im plementation
The optimizer is an important function in this PBPK model, which can

automatically find the best pharmacokinetics parameters by giving a good fit
compared to the experiment data. An “error_fun” is implemented to compute the
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error between the simulation and the experimental data in the least square. A
num ber o f controllers are coded which can be turned on or off in the parameters to
optimize. The “opt_matrix” stores all parameters that attempt to optimize. A
M atlab optim ization method called “fminsearch” is used for the PBPK model.
•

XM L files Implementation
The XM L files are implemented from the XM L design table. The XM L root

element is corresponded to the first level element in XM L file table. The X M L sub
elements are related to second level elements, and so on. W hen the XM L file is
implemented, a testing in IE was performed. The XM L parse tool box was
downloaded from www.mathworks.com. Reading Xml file into the program was
performed by the “xml_read” method, and by writing the data into the XM L file
was performed by the “xml_fprint” method implemented by myself.

3.2.3 U ser In terfa ce Im plem entation
The user interface is implemented by “Guide” tool after all source codes done and
tested. “G uide” Tool provides most useful widgets and a nice IDE. You can drag widgets
into canvas and locate its place according to your design, then implement the event in the
callback function. The “Begin PBPK M odel” will be built first, then hooked into the
PBPK model and tested it. Second, I implemented “Parmaeters Adjusted Block” area.
Third, the display area and output figures are implemented. In addition, the menu and
some help functions are added into the main user interface. To get a good feedback, some
dialog boxes are integrated into the user interface.
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3.3 Testing
There are two testing methods involved in the implementation. During the
programming, I followed the first testing method (unit testing): after a function was
coded, a unit testing was followed. The purpose is to find whether the function worked
and achieved the design aim. Second testing method is called the integrated testing —
integrating many functions together and testing whether those can do the right jobs.
W hen some errors were found, a debugging tool was used to debug and track where the
problem happened. During the integrated testing, I used a number of cases to test all
possible problems. W hen the problem was found, it was fixed immediately.
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SECTION 4: RESULTS
4.1 The Relationship between O rgans’ Volume and Age

Organ volumes for a total of 23,028 records are calculated using the regression
equations described in appendix Table 1. Figure 5 shows the data on body weight, body
height, and calculated twelve organ volumes as a function o f age, for the individuals
accumulated from the above-cited databases, along with the regression fits. The results
are com parable to the outputs from Physiological Parameters for PBPK M odeling P3M
[9]. Blood flow rate for each organ is then calculated by multiplying the organ volume
by its perfusion rate, which has units o f volume o f blood per minute per volume o f organ
[9]. W ith these validated scaling equations, it is possible to model inter-individual
variation in the physiological parameters across a population o f interest. Note
correlations between age, gender, race, and body weight and body height must be
captured in sampling the population.

Protein concentrations of albumin and ORM2 as a function o f age are described by a
simple model proposed by M cNamara [12] as follows:

^albumin

Q>rm2

infant = (0.005627 Xagc + 76.7) x

in adult

infant = (0.01137xage + 53.4) x Cqr^,2 ^ adult

(9)

(10)

where the concentration o f ORM2 ( Corm2 ) replaces the concentration o f AAG (

) in

the original equation given by M cNamara and A lcom [12]. For enzyme activity level,
the infant scaling factor (ISF) proposed by A lcom and M cNamara [12] is used. However,
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based on the developmental data given by Stevens [13], the relative enzyme activities of
CYP3A4 and 3A7 are updated using following equations:

ISF o f enzym e CYP3A4 = 1 0 2 3 0 - 1 2 0 . 5 x age + 2310) /6 4 ,
age < 2 1 .7 years,

(11)

ISF of enzyme CYP3A7 = 1.64 / (age + 0.1066), age < 1 .5 years.

( 12)

where age is expressed in years. In this work, the kinetic parameters (

and

) of

CYP3A4, 3A5, and 3A7 for metabolism o f drug are assumed to be equal.
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female and the blue points represents the male.
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4.2 M odel Validation Results

In order to validate this constructed PBPK model, experimental data o f three drugs,
methadone, fentanyl and nevirapine, are selected from clinical studies on adults in
literature. These validations include the administration in oral and IV, and single and
multiple dosages.

4.2,1 M ethadone Validation
•

Single dosage
Figure 6 shows a comparison of the PBPK model simulation versus the

experimental data for the arterial plasma concentration of racemic methadone. The
fitting experimental data is based on Khaeseh, E D., et al [8]. Drug dose is 0.14
(mg/kg), IV administered in two minutes; the simulation time step is one minute,
and the simulation is ended in 96 hours; nine organs (liver, intestine, kidney, brain,
lung, muscle, lipid, heart, skin) were integrated into this PBPK model. An
optim izer was used in this model to adjust the partition parameters and M ichaelisM enten constants (Vm, Km) in order to fit the experimental data. The mean error,
the root error, and the correlation coefficient between the simulation and
experiment data are 0.0005, 0.0122, and 99.46% respectively. As seen in Figure 6
and the above error and correlation data, the simulation curve matches the
experimental data well.
•

M ultiple dosages
Figure 7 illustrates a simulation o f plasma (S)-methadone based on the
normalized data of 18 patients given a dose of 70mg/kg. The dose is
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administered orally every 24 hours. The time to achieve steady-state
pharmacokinetics is assumed to be 10 days. The experimental data is based on
Kharsch E.D., et al [8]. There is a 3.0 fold increase in total clearance from the
first dose to steady-state dose. The red trend line is fitted by the addition of two
exponential functions. It indicates that the concentration of the drug increases
exponentially. Figure 8 shows the observed versus simulation data in the tenth
day. The mean error, the root error, and the correlation coefficient between
simulation and experiment data are -0.033, 0.037, and 73.57% respectively.
These two curves fit closely. It clearly shows that the simulation curve is very
close to experiment data and it agrees with the paper, which says in the paper
[14]. There is a 3.5 fold increase in total clearance from the first dose and the
steady-state dose,
A simulation of plasma methadone in blood
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Figure 6: Plasm a concentration o f methadone versus time
after 0.06mg/kg IV dose o f racemic methadone
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Figure 8: Plasm a concentration o f methadone versus time in the tenth day
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A simulation of plasma (R) and (S)-methadone
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Figure 9: Plasma concentration o f methadone versus time
on multiple methadone injections of oral and IV

Figure 9 shows data analysis from Kristensen [15] on multiple methadone
injections o f different types. The experimental data was collected from patient #5
who is given 10 mg tablet at the time 0 hour and lOmg IV at the 48th hour [15].
During the simulation, only the V^ax and the basic partition coefficient are adjusted.
All the other parameters are set to the population averages for individuals of the
reported sex, height, and weight o f the five patients from Kristensen, et al [15]. The
mean error, the root error, and the correlation coefficient for R-M ethadone and SM ethadone between the simulation and the experimental data are -0.0215, 0.0318,
and 79.28%, and 0.0096, 0.0375, and 58.24 respectively. Figure 9 shows that there
is a good match between the simulation and the experimental data for both (R) and
(S)-methadone.
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Figure 11 : Plasm a concentration o f nevirapine versus time on a single dosage
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4.2.2 F en ta n yl Validation
The pharmacokinetics of fentanyl was found from the paper [16], and Vmax and
were based on the paper [17]. Figure 10 shows a comparison between the PBPK model
simulation and the experimental data for the arterial plasma concentration. The fentanyl
dosage is 0.1 mg/kg fentanyl in 2 minutes by IV administration. The mean error, the root
error, and the correlation coefficient for Fentanyl between the simulation and the
experimental data are -0.0579, 0.0798, and 89.43% respectively. These two curves fit
very well except for the time period from the 5^ hour to the 12*** hour.
4.2.3 N evirapine Validation
The pharmacokinetics of nevirapine was found in the papers [18], [19]. Figure 11
illustrates a comparison between the PBPK model simulation and the experimental data
for the arterial plasma concentration by given 5.71 mg/kg dose in 1 minute; Model fit is
obtained by varying the basic partition coefficient and the CYP3A4 enzyme activity
(Vmax)- The tissue (organ) / blood partition coefficients proportions were fixed during the
simulation. No data about Vmax and Km in literature are available in literature, thus a
ratio of V^ax : K ^ was obtained by fitting the experimental data in the liver metabolized
by enzyme CYP 3A4. Accordingly, Vmax and Km were calculated as 0.0001313
nmol/min/mg protein and 10.0 umol/L. The mean error, the root error, and the
correlation coefficient for Nevirapine between the simulation and experimental data are
-0.0579, 0.0798, and 89.43% respectively. Figure 11 shows there is a good agreement
between the simulation and experimental data, however, during the first couple hours,
mismatch was observed.
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4.3 The Prediction o f The PBPK Model
Figure 12 illustrates the concentration distribution o f methadone in different organs.
The param eters are the same as in Figure 6. Apparently the concentrations in each organ
are quite different. W ith a close look at Figure 12, we observe that the difference in
partition coefficients of organs is the major source for the concentration difference.
Figure 13 illustrates that the plasma concentration as a function of the time and patients
ages. In this model the parameters are the same as in Figure 6. It clearly indicates that it is
possible to simulate drug plasma concentration in different ages by scaling the enzyme
Vmax, ISF and the organ volume according to the validated adult model. Figure 13
shows the predicted concentration curve for seven male subjects aged 1, 3, 5, 10, 20, 30
years. Figure 13 and Figure 14 show that the peak concentrations are reached after about
1-2 hours. Given the same dosage for different age patients, the plasma concentrations of
methadone increased linearly.
The distribution of methadone concentration in each organ
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Figure 12: Plasma concentration of methadone versus time in each organ
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The concentration vs time in different ages
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Figure 13: Plasm a concentration of methadone for different ages
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Figure 14: Plasma concentration o f methadone for different ages during 0—12 hours
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4.4 U ser In terfa ce
The main window user interface is shown in Figure 15. It includes a menu toolbar,
which allows the user to create a patient, a drug and a body setting, and edit or delete
them. The “Begin PBPK M odel” block is simple and easy to use. It includes selecting a
patient, choosing a drug, giving a prescription, and executing this Model. A first time
user can find the introduction by clicking the “Quick PBPK Introduction” button. During
the modeling, the user can customize the parameters such as patient information, drug
partition coefficient, kinetics and optimizer setting according to the pharmacokinetic of a
drug. Finally, it can display the concentration curves in two other windows, and it can
display the AUC and half life in the main window.

36

Patient

Body Setting

Drug Setting

Help

Quick PB PK Introduction

— - —--------- ------------ ———------

B cyin PBPK M odoi

Step 1 : S e le c t P atient

N am el

Step 2:

S e le c t Drug

Methadone

Step 3:

Prescription
D o se (m g)

o.14

Injection/Oral IV

Step 4:

— -------------------------

jj

jJ

Load E xperim ent D ata Methadone Datai

Infusion Tim e(m in)

2

Lasting Tim e(h)

Interval Tim e(h)

0

V ector Tim e(h)

jj

C om pute & Plot

-----------M etabolism P ara m

Partition Coefficient

Km

Vm
Age(year)

30

Muscle

10.5

9999

0

Welght(Kg)

gg

Liver

44.2

0.0013

10.87

Height(cm)

170

Kidney

76.6

9999

0

Intestine

37.2

0.00123

Lung

156.3

9999

Basic

0,5

Race White
Gender p
Pka

- [
J

0.04

96

R eset

Parameters Adjusted Block
P atien t

Exit

O ptim izer P a ra m

O On/Off Optimizer

[ ^ 11.0

1

~0~

□ Using Scaling

U pdate & Plot
D isp lay P a tie n t A nd D rug P h a r m o c o k in e tic s
P atient N am e

Tom P ark

Drug N am e

m eth ad o n e

smuiaBon

Drug P harm ocokinetics

AUC(um/ml):

2.4731

HalfTime(h):

2 3 .3 5 4 9

Ctearance(mol/h):

0 .0 2 5 7 6 2

Figure 15: PBPK Model main window

37
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4.5 Sum m ary o f Features

1) The PBPK model provides a set of default human body standard physiology
parameters (organ volume, blood flows, organ weight) for patients of different
race. Those default parameters highly reduce the user input and increase the
efficiency.
2) The output includes both the pharmacokinetics data and the concentration curve.
It is separated from the main program, therefore allowing user to simply save
files.
3)

It has a friendly user interface which allows users to leam and to use easily. It
also has a fast and good feedback.

4) The model provides the flexibility for the user to build the customized model
structure (organ selections, protein selection, enzyme selection).
5) A customized optimization function is provided, which allows users to optimize
the parameters.
6) An age-deepened scaling module is included, which can predict a more accurate
concentration for children.
7) The IV and Oral input module are integrated into the PBPK.
8) The whole program is built with separate module software packages, which can
be more extendable.
9) All data sources are stored and read through the portable XML files. The XML
files are independent o f platforms and can be displayed on the web easily.
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SECTION 5: CONCLUSION AND FUTURE WORK

The distribution o f drugs in the human body is complex and affected by many
factors such as the blood flow, the permeability of membranes, the volume o f tissues and
the physicochemical characteristics o f drugs. Based on the assumptions mentioned in
Section 2, the new PBPK model has been constructed, and can perform a general purpose
systematical drug study. It also can be adapted to explore the novel situations such as
multiple dosages and other drugs. The developed PBPK model includes whole-body
multi-organ distributions, plasma protein binding, metabolism, and a scaling module. The
parameterization of this module is based on a database of PK parameters and data
collected from clinical experiments. This new PBPK model also has a friendly user
interface, making it easy to leam and to use. Adiditionlly, it provides customization
flexibility such as organ selections, and communication flexibility (i.e., the XM L storage
of drug and the patient information, and the hum an body setting standards). The new
PBPK model is also open source and free distribution.
This new model is still simple and does not model the urine clearance, the bonus
input and the dm gs’ interaction. The speed of the optimizer is slow. In the future, we
should add a drug interaction module into the new PBPK, and implement all general drug
types administered. If possible, implementing the PBPK model on a web server would
allow users access from the Internet. Another approach is to build a database including
the detail pharmacokinetics for m ost drugs. It will reduce users’ efforts to find these data
and save time.
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APPENDIX A; TABLES
Table 1: A list PBPK model software online
Software name
AcslXtreme

Advantage
Classical PK, PBPK, and PD Modeling, optimization,
graphic interface and not require explicit coding of the
model equation

Commercial product, not open source,
lack extendibility

ADAPT

Simulations, non linear regression, and optimal
sampling. Includes extended least squares and
Bayesian optimization

No user interface input, require coding
the model equation, require system
support Fortran language

http://www.boomer.org/pkin/soft.html

Berkeley
Madonna

Berkeley Madonna is arguably the fastest, most
convenient, general purpose differential equation
solver available today.

Require coding the whole PBPK model

http://www.berkeleymadonna.com/

Biokmod

Biokmod can be applied for solving system of
differential equations, fitting coefficients, convolution,
and for modeling Linear and Nonlinear Biokinetic
Systems.

Not complement PBPK model, solves
simple bio-mathematic problem

http://www3.enusa.es/webMathematica/
Public/biokmod.html

JGuiB

most commonly used functions of Boomer in PK/PD
modeling included: normal fitting, simulation and
Bayesian estimation; adjustable parameters; more
convenient in computer-aided teaching of PK/PD
modeling.

Not open source, hard to use. Not support http://jguib.pkpd.org.tw/
extendibility, and no scaling
functionality, commercial

JavaPK for
Desktop

Users can define their own model with population PK
parameters using either a single-dose, integral equation
(for the multiple-dosed) or a steady-state integral
equation. The user defined Bayesian model can also be
easily applied for the purpose of clinical PK or TDM.

Free software, none open source. No
scaling functionality

SAAMII,

Has a graphic tool for developing PBPK structures;
Creating systems of ordinary differential equations

Commercial, not open source, lack
ittp://www.saam.com
extensibility, not allow good control over |

Disadvantage
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website
http://www.aegisxcellon.com

http://jpkd.pkpd.org.tw/

from the compartmental model structure; Permitting
the simulation of complex experimental protocols on
the model. Solving the model and fitting it to data
using state-ofthe-art mathematical and statistical
techniques.

the model equations. Not support scaling
functionality.

WinNonlin

It is a big Industry-Standard PK/PD Modeling and
Analysis package. Not specific for PBPK model.
Support user interface and does not require coding of
the model functionalities.

Commercial product, not open source, not http://www.pharsight.com
allows good control over the model
equations. No support scaling
functionality.

PKQuest

Provide a general purpose for PBPK model, including
“Standardhuman” and “standardrafuser interface,
optimizer routine. A free and open source product

It is implemented in Maple. When you
run this product, you have to install
Maple first. It does not include scaling
function.
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www.pkquest.com

Table 2: A collection of regression equations to calculated organ volumes based on age, gender, body weight, and body height.
Tissue and Age Range
Sex
Sources
Regression Equation
Blood volume (ml)
M
Sprenger 1987
[> H ]
{ l 3 . l x B H + l S . 0 5 x B W - 480)/0.5723
F
Sprenger 1987
(35. 5XBH + 2.21 X B W - 3 3 S 2 ) ! 0.6m
[2-14]

M

J Q0.6459xlog 10( BW )+0.002743xB//+2.1324

Linderkamp 1977

F[2-7]

jQ0.6459xlogl0(BH^)+0.002743xB//+2.1324

Linderkamp 1977

F[7-14]

jQ0.6412xlogl0(BW)+0.001270xBW+2.3169

Linderkamp 1977

[0-2]

MF

jQ0.7891xlogI0(BW)+0.004132xBH+1.8117

Linderkamp 1977

Adipose volume(ml)

M

(0.99 x B M I - l .32) / 100x BW / 0.923 x 1000

Gray 1990

F

(1.20xBM/-k0.23xfl^e-5.4)/100x5W/0.923xlOOO

Gray 1990

M

{ B W x l O O O - adipose vo/wmex 0.923)x 0.54/1.04

Clarys 1984

F

( B W x l 000 - adipose volume x 0.923) x 0.489 /1.04

Clarys 1984

Muscle volume(ml)
[>18]

[<18]

Heart volume (ml)

Skin volume (ml)
[<1]
[1-10]
[>18]
Liver volume (ml)
[>19]
[<19]
Spleen Volume (ml)
Kidney Volume(ml)

M

(0.0133Xfl^e-l-0.30)x (5 iy ^lOOO-adipose W w m ex 0.923)/1.04

F

(0.0105X

M

22.81x(BW/100)xBlV‘” -4.15

Ogiu 1997

F

19.99x(B///100)xBlV"^ -1.53

Ogiu 1997

MF
MF
MF

BSAX618
BSAX663.4
BSAX 1834.5X1.04

Bailey 1996
Bailey 1996
Bailey 1996

MF

0.05012XBW°^'XlOOO
(576.9X(Bff/100) + 8.9XB1V-159.7) 71.08
(674.3X (BW/lOO) + 6.5XB1V-214.4)/1.08

Noda 1997

M
F
MF

6.516X

4-0.30)X (BW x \ 0 { ^ - adipose va/«w ^x 0.923)/1.04

Ogiu 1997
Ogiu 1997
Watanabe 1997

[>221
[<22]

MF
M

(15.4 + 2.04X5H^+ 51.8X (BH/100)^2)/1.04
leftKidneyWt= 10.24X (fiff/100) X

+7.85;

Kasiske 1986
Ogiu 1997

rightKidneyWt = 9.88X (BH/100) X BlV“ ’ +7.2;
total kidney volume = (leftKidneyWt + rightKidneyWt)/L04;
F

leftKidneyWt = 10.65 X (BW/IOO) X

6.11;

Ogiu 1997

rightKidneyWt = 9.88X (BH/lOO) X
’ + 6.55;
total kidney volume = (leftKidneyWt + rightKidneyWt)/1.04;
Brain Volume(ml)

MF

(1.449-3.62/fîW) X 1000/1.04;

Dekaban 1978

Lung Volume (ml)

M

leftLungWt = 29.08X (Bm 00)X gW "^+11.06;

Ogiu 1997

rightLungWt = 35.47X (BW/lOO) X
+5.53;
total lung volume = (leftLungWt + rightLungWt)/1.04;
F

leftLungWt = 31.46x (BH/lOO) x B W “’ +1.43;

Ogiu 1997

rightLungWt = 35.30X (Bfl/100) X BW^^+1.53;
total lung volume = (leftLungWt + rightLungWt)/1.04;
Pancreas Volume (ml)

Thyroid Volume (ml)

Glorgans Volume(ml)

M

(7.46X (Bff/lOO) X BIV"’ 4).79)/1.04

Ogiu 1997

F

(7.92X (BB/100) X Biy"*-2.09)/1.04

Ogiu 1997

M

(1.46X (BHim) X BlV‘” -0.33)/1.04

Ogiu 1997

F

(1.17X (BH/m) X BlV®^-0.29)/1.04

Ogiu 1997

M
F

0.021 X (BWX1000 - adipose volumeXO.923) /1.04
0.027 X {BW X 1000 - adipose volume X 0.923) /1.04

* Body surface area (BSA, unit ^ ) are calculated by Mosteller formula: BSA = sqrt({BHXBW)/3600 ).
** BMI = BW/(BH/100)^
*** All references in source column can be found in [7]

4^

Table 3: Patient data [Root: PatientDT]
Level 1
Name [Name]

L evel!
Fname
[FName]
Lname
[LName]

Level3

Element type

Note

String
String

Gender
[Gender]
Age [Age]
Race [Race]
Height [Height]
Body weight
[BodyWT]
Body Surface
area [BSA]

String

“F/M”

Integer
String

Year
White, black, Asian, Indian,
Arabian, etc

Float

cm

float
float

* [XXX] represents the element in XM L file
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__

kg
m^2

Table4: Anatomical parameters for a normal white male [Root: DT]
Level 1

Basic information
[BBasicInfo]

Level2
Body Weight [BodyWT]
Body Height [BodyHT]
Cardiac output [TotalQ]
Total Volume
[TotalV]
Blood Volume [VBlood]
Body Fat [BFat]
Body Liver WT
[BLiverWT]
Body Density [BDensity]
Body MP [BMP]
Body ISF [BISF]
Body PH [BPH]
Gender [Gender]
Race [BRace]
Blood Flow [Q]

Vein [Vein]

Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]

Value
70
170
5.8

Kg
Cm
Liters/min (5.8, 5.18)

85
5.9
0.2

Liters
Percentage of body weight
Fat ratio for a standard man

1820
1.1

g
density
mg o f microsomal protein/g
o f liver
no
no
Male
White

52.5
1.0
7.4
M
White
5.8
2.54
3431
0.5948
0.82
1.06
5.8

Note

ml/min. Blood flow
liter
g

g/cm"^3
ml/min. Blood flow
liter

Artery [Artery]

Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]

Liver [Liver]

Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]

1.59
2148
0.5948
0.82
1.06
1.1085
1.799
1820
0.23
0.7
1.08
0.822

Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]

0.637
1175
0.3
0.78

liter

Density [Density]

1

g/cm*3

Intestine [Intestine]
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g

g/cm^3
ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow
g

1.0916
0.28
310
0.165
0.8
1
0.5905
1.4
1680
0.2
0.8
1
5.8
0.805
536
0.2
0.8
1
0.863
29.0
26000
0.15
0.78
1
0.338
18.185
17000
1
0.20
0.923
0.223
0.332
330
0.25
0.8
1

Skin
[Skin]

Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecfl
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]

Spleen

Water Fraction [WFract]
Density [Density]
Blood Flow [Q]

0.70
1
0.13

Kidney [Kidney]

Brain
[Brain]

Lung
[Lung]

Muscle
[Muscle]

Adipose
[Adipose]

Heart
[Heart]
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0.379
3.1611
2600
0.60

ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow
liter
6 _

g/cm^3
ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow
liter
g

g/cm^3
ml/min. Blood flow

[Spleen]

N ewl
[New I]

Others
[Others]

Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
Blood Flow [Q]
Volume [V]
Weight [WT]
Extracellular fraction [Ecf]
Water Fraction [WFract]
Density [Density]
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0.13
130
0
0
1
0.1
0.1
0
0
0
1
0.1
0.1
0.1
0.1
0.1
1.04

liter
g

_

g/cm^3
ml/min. Blood flow
liter
g

g/cm'^3
ml/min. Blood flow
liter
g

g/cm^3

_

Table 5: Drug related PBPK parameters [Root: DrugParams]
Level 1

Level2

Value

Note

Drug Name [DrugName]
Drug Molecule Weight
[DrugMolWt]
Drug Oral bioavailability
[DrugOralF]
Drug Absorption rate
[DrugAbsorptRt]

Methadone

A drug name

309.0

309.0 for methadone

0.9

Oral bioavailability

0.1

Absorption rate, min^-1

Drug VD [DrugVd]

4.5

Liters/kg

Drug PKa [DrugPka]

9.2

Liters/kg

180

Hour

0.7314

Um/L

Drug Tmax [DrugTmax]
Drug
Basic Info
[DrugBasi Drug Cmax [DrugCmax]
clnfo] Basic Partition Coefficient
[ParCoef]
Prescription
[DrugPrespt]

Levels

0.5
Dose [Dose]

0.2

InputType [InputType]

1

mg/kg
If 1 represents IV, other 2
whiles oral (1/2)

Infuse Time [FVTime]
Lasting time
[LastingTime]

2

min

96

hour

12

hour

0

hour

Interval Time [IntvlTime]
Interval Vector Time
[IntvlVct]
Vein
[Vein]

Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

Protein 1

1
1

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice
Kml
Vml
Km2
Vm2

[SiteChoice]
[Kml]
[Vml]
[Km2]
[Vm2]

Infant Scaling Factor[ISF]
Name [Name]

50

1
9999
0
9999
0
1
ORM2

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product o f permeability
surface area
0 represents no, 1 represents
yes
Vi, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

[Protein 1]

Clearance
[Clearance]

Protein Molecule
[ProteinMol]

23513

Have [Have]
Concentration [Cone]

1
33.33

1
SiteChoice [SiteChoice]
Binding Constant K1 [Kl]
0.152
Binding Constant K2
[K2]
0.005208
0.02
Unbound fraction [Fu]
Infant Scaling Factor[ISF]
1
Have Clearance [Have]
0
Clearance [CL]
0

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

Artery
[Artery]

Protein 1
[Protein 1]

Clearance
[Clearance]

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
^2, 1 represents one site, 2
represents two sites
0.38*4.0e+5/le+6
8.4*620/le+6
Unbound fraction

0.12
1
1

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Kml [Kml]
Vm l [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
0
9999
0
9999
1
ORM2

Have [Have]
Concentration [Cone]

0
6.6685

SiteChoice [SiteChoice]
Binding Constant Kl [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]
Have Clearance [Have]
Clearance [CL]

1
0

Protein Fu
[PFU]

0 represents no, 1 represents
yes
^2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

0
0.02
1
0
0
0.12
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0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area

0 represents no, I represents
yes
0.78/protein_moIWt* le+6
‘/ 2, 1 represents one site, 2
represents two sites

Unbound fraction

Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

Liver
[Liver]

Protein I
[Protein 1]

Clearance
[Clearance]

Kidney
[Kidney]

1
44.2

Name [Name]

0
CYP3A4

Have [Have]

1

SiteChoice [SiteChoice]
Kml [Kml]
Vml [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor[ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
10.87
0.0013
188.33
0.015
1
ORM2

Have [Have]
Concentration [Cone]

1
16.6

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor [ISF]
Have Clearance [Have]
Clearance [CL]

1
0.152

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area
0 represents no, 1 represents
yes
*/2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

0.0052
0.02
1
0
0

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
V^2, 1 represents one site, 2
represents two sites

Unbound fraction

0.12
1
76.6

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice
Kml
Vm l
Km2
Vm2

[SiteChoice]
[Kml]
[Vml]
[Km2]
[Vm2]

Infant Scaling Factor[ISF]
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1
0
9999
0
9999
1

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product o f permeability
surface area
0 represents no, 1 represents
yes
V2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

Protein 1
[Protein 1]

Clearance
[Clearance]

Intestine
[Intestine]

Name [Name]
Protein Molecule
[ProteinMol]

ORM2

Have [Have]
Concentration [Cone]

0
11.6106

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]
Have Clearance [Have]
Clearance [CL]

1
9999

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme I ]

Protein 1
[Protein 1]

Clearance
[Clearance]

23513

9999
0.02
1
1
0.023

0 represents no, I represents
yes
0.78/protein_molWt* Ie+6
V2 , 1 represents one site, 2
represents two sites

Unbound fraction

0.12
1
37.2

Name [Name]

0
CYP3A4

Have [Have]

1

SiteChoice [SiteChoice]
Kml [Kml]
Vm l [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
11.0
0.00123
1160
0.0012
I
ORM2

0
2.234

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]

1
9999

53

0 represents no, 1 represents
yes
V^2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

Have [Have]
Concentration [Cone]

Have Clearance [Have]
Clearance [CL]

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area

9999
0.02
1
0
0.023

0 represents no, I represents
yes
0.78/protein_molWt* le+6
Vz, 1 represents one site, 2
represents two sites

Unbound fraction

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme I]

Brain
[Brain]

Protein 1
[Protein 1]

Clearance
[Clearance]

Lung
[Lung]

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]
Enzyme 1
[Enzyme 1]

0.12
1
4.6

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Kml [Kml]
Vml [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
0
9999
0
9999
1
ORM2

Have [Have]
Concentration [Cone]

0
3.3173

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor [ISF]
Have Clearance [Have]
Clearance [CL]

1
9999

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area
0 represents no, 1 represents
yes
‘/ i, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

9999
0.02
1
0
0.023

0 represents no, 1 represents
yes
0.78/protein_molWt* le+6
Î/2, 1 represents one site, 2
represents two sites

Unbound fraction

0.12
1
156.3

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice
Kml
Vm l
Km2

[SiteChoice]
[Kml]
[Vml]
[Km2]

Vm2 [Vm2]
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1
0
9999
0
9999

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product o f permeability
surface area
0 represents no, 1 represents
yes
*/2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

Protein 1
[Protein 1]

Clearance
[Clearance]

Muscle
[Muscle]

Protein!
[Protein 1]

Clearance
[Clearance]

23513

Have [Have]
Concentration [Cone]

0
11.6106

SiteChoice [SiteChoice]
Binding Constant Kl [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor [ISF]
Have Clearance [Have]
Clearance [CL]

1
9999

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

1
ORM2

9999
0.02

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
Vi, 1 represents one site, 2
represents two sites

Unbound fraction

1
0
0.023
0.12
1
10.5

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Kml [Kml]
Vm l [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor[ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
0
9999
0
9999
1
ORM2

Have [Have]
Concentration [Cone]

0
16.5866

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]

1
9999

Have Clearance [Have]
Clearance [CL]

0
0.023
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0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area
0 represents no, 1 represents
yes
1/2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

9999
0.02
1

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
Vi, 1 represents one site, 2
represents two sites

Unbound fraction

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

Adipose
[Adipose]

Protein 1
[Protein! ]

Clearance
[Clearance]

Heart
[Heart]

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]
Enzyme!
[Enzyme!]

0.12
0
2.95

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Km! [Kml]
Vm! [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor[ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
0
9999
0
9999
1
ORM2

Have [Have]
Concentration [Cone]

0
11.6106

SiteChoice [SiteChoice]
Binding Constant Kl [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]
Have Clearance [Have]
Clearance [CL]

1
9999

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area
0 represents no, 1 represents
yes
V2 , 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

9999
0.02
1
0
0

0 represents no, 1 represents
yes
0.78/protein_molWt* le+6
V^2, 1 represents one site, 2
represents two sites

Unbound fraction

0.12
0
24

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Kml [Kml]

1
0

0 represents no, 1 represents
yes
*/2, 1 represents one site, 2
represents two sites
umol

Vm l [Vml]
Km2 [Km2]
Vm2 [Vm2]

9999
0

Nmol/min/mg
umol

9999

Nmol/min/mg
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Protein 1
[Protein 1]

Clearance
[Clearance]

Skin
[Skin]

Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
ORM2

Have [Have]
Concentration [Cone]

0
16.5866

SiteChoice [SiteChoice]
Binding Constant Kl [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]
Have Clearance [Have]
Clearance [CL]

1
9999

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

Protein 1
[Protein 1]

Clearance
[Clearance]

23513

9999
0.02
1
0
0.023

0 represents no, 1 represents
yes
0.78/protein_mol Wt* 1e+6
Vi, 1 represents one site, 2
represents two sites

Unbound fraction

0.12
0
2.8

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Kml [Kml]
Vm l [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor [ISF]
Name [Name]
Protein Mo]ecule
[ProteinMol]

1
0
9999
0
9999
1
ORM2

0 represents no, 1 represents
yes
Vi, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

Have [Have]
Concentration [Cone]

0
8.0933

SiteChoice [SiteChoice]
Binding Constant K l [Kl ]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor [ISF]

1
9999
9999
0.02
1

Have Clearance [Have]

0

Clearance [CL]

0.023
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0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
Vi, 1 represents one site, 2
represents two sites

Unbound fraction

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

spleen
[Spleen]

Protein 1
[Protein 1]

Clearance
[Clearance]

New
[Newl]

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]
Enzyme 1
[Enzyme 1]

0.12
0
20

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice [SiteChoice]
Kml [Kml]
Vm l [Vml]
Km2 [Km2]
Vm2 [Vm2]
Infant Scaling Factor[ISF]
Name [Name]
Protein Molecule
[ProteinMol]

1
0
9999
0
9999
1
ORM2

Have [Have]
Concentration [Cone]

0
0

SiteChoice [SiteChoice]
Binding Constant Kl [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor [ISF]
Have Clearance [Have]
Clearance [CL]

1
9999

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product o f permeability
surface area
0 represents no, 1 represents
yes
16, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

9999
0.02
1
0
0.023

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
'/z, 1 represents one site, 2
represents two sites

Unbound fraction

0.12
0
1

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice
Kml
Vm l
Km2

[SiteChoice]
[Kml]
[Vml]
[Km2]

Vm2 [Vm2]
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1
0
9999
0
9999

0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area
0 represents no, 1 represents
yes
*/2, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

Protein 1
[Protein 1]

Clearance
[Clearance]

Others
[Others]

Protein 1
[Protein 1]

0
0

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2
[K2]
Unbound fraction [Fu]
Infant Scaling Factor[ISF]
Have Clearance [Have]
Clearance [CL]

1
9999
9999
0.02
1
0
0.023

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
*/2, 1 represents one site, 2
represents two sites

Unbound fraction

0.12
1
2.87

Name [Name]

0
CYP3A4

Have [Have]

0

SiteChoice
Kml
Vm l
Km2

[SiteChoice]
[Kml]
[Vml]
[Km2]

1
0
9999
0

Vm2 [Vm2]
Infant Scaling Factor [ISF]
Name [Name]
Protein Molecule
[ProteinMol]

9999
1
ORM2

Have [Have]
Concentration [Cone]

0
0.25

SiteChoice [SiteChoice]
Binding Constant K l [Kl]
Binding Constant K2 [K2]

1
9999
9999
0.02

Unbound fraction [Fu]
Infant Scaling Factor
[ISF]
Clearance
[Clearance]

23513

Have [Have]
Concentration [Cone]

Protein Fu
[PFU]
Participate
[Participate]
Partition Coefficient
[PartitionCoeff]
Permeability surface
[PS]

Enzyme 1
[Enzyme 1]

1
ORM2

Have Clearance [Have]
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0 represents no, 1 represents
yes
The ratio concentration
between vein and this organ
The product of permeability
surface area
0 represents no, 1 represents
yes
Vi, 1 represents one site, 2
represents two sites
umol
Nmol/min/mg
umol
Nmol/min/mg

23513

1
0

0 represents no, 1 represents
yes
0.78/protein_molWt* 1e+6
Vi, 1 represents one site, 2
represents two sites

Unbound fraction

Clearance [CL]
Protein Fu
[PFU]

0.023
0.12

60

Clearance [CL]
Protein Fu
[PFU]

0.023
0.12
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Table 6: Optim izer control table [Root: CMDT]
Level 1
Optimizer
Control
[OptDT]

Level 2

Vein [Vein]

Level2
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Artery
[Artery]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Liver
[Liver]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Intestine
[Intestine]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]
Protein 1 [ProteinDT]

Kidney
[Kidney]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
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Value
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
1

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Brain
[Brain]

Levels

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

0
0
0
0
0
0
1
0
0
0
0
0

0

Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Lung
[Lung]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Muscle
[Muscle]

Adipose
[Adipose]

Heart
[Heart]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]
Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]
Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]
Protein 1 [ProteinDT]

Skin
[Skin]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
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1
0
0
0
0
0
0
1
0
0
0
0
0
0

Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]

Enzyme 1 [EnzymeDT]

1
0
0
0
0
0
0

Vm [VmDT]
Km [KmDT]

1
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0

Spleen
[Spleen]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

N ew l
[N ew l]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]

Others
[Others]

Protein 1 [ProteinDT]
Volume Optimizer [VDT]
Blood Flow Optimizer [QDT]
Organ Weight Optimizer [WtDT]
Partition Coefficient Optimizer
[PtnDT]
Enzyme 1 [EnzymeDT]
Protein 1 [ProteinDT]

* value 0 - no optim ization set, and 1 - optimization set
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Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

0
0
0
0
1
0
0
0
0
0
0
1

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

Vm [VmDT]
Km [KmDT]
Concentration [ProteinDT]

0
0
0
0
0
0
1
0
0
0

Table 7. Anatomical parameters used in the PBPK model for a normal white male
Organ name
Xp
Body weight (kg)
Body height (cm)
veins
arteries
liver
kidney
intestine
lung
brain
spleen
muscle
adipose
heart
skin
pancreas
thyroid

75
177
3431
2148
1454
318
1175
967
1346
139
30226
18185
332
3387
109
21

Blooc flow (ml/min)
UF
IF

Volume (ml)
UF
IF

Xp

1.24
105
1.05
1.05
1.05
105
105
1.05
105
1.05
1.05
1,05
1.05
1.05
1.05
1.05

6445.65
6445.65
1221.34
1170.11
881.620
6445.65
686.89
139.45
906.80
363.70
242.51
406.46
65.51
106.00

-0.049
-0.051
-0.092
-0.049
-0.048
-0.063
-0.050
-0.047
-0.064
0.013
-0.062
-0.051
-0.066
-0.058

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

-0.055
-0.046
-0.072
-0.051
-0.058
-0.047
-0.059
-0.036
-0.053
0.005
-0.069
-0.058
-0.056
-0,054

* Uncertainties associated with blood flows are assumed to be fully correlated with organ
volumes.
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Table 8: Drug-related PBPK parameters for (R)- and (S)-methadone
Parameters
Xp
Absorotion
bioavailability
absorption rate(min-l)
Protein binding
ORM2 cone [ //m /I]
k(ORM2) [l/(//m /L )]
Clearance
Knax [
/min/mg protein]
Km [///w /L ]
urine pH
renal clearance [ml/min]
Partition coefficients
veins
arteries
liver
intestine
kidney
brain
lung
muscle
spleen
heart
adipose
skin
pancreas
thyroid

(R)-methadone
UF
IF

Xp

(S)-methadone
UF
IF

85%
6.15e-3

1.4
2

0.0443
-0.0066

85%
6.10e-3

1.4
2

0.0443
-0.0066

6.6685
0.8532

4
1

0.0585
0

6.6685
1.2432

4
1

0.0585
0

9.433e-3

5

-0.1243

2.760e-3

5

-0.091

198
7.4
23.0

2
1.2
1

0
0.0216
0

182
7.4
13,2

2
1.2
1

0
0.021
0

1
1
15.61
4.104
6.773
1.624
28.18
2.114
9.350
4.01
le-6
le-6
le-6
le-6

1
1
3.00
9.00
12.0
3.00
6.00
7.00
7.00
3.00
1
1
1
1

0
0
-0.013
-0.014
-0.009
-0.013
-0,042
-0.033
-0.045
-0.033
0
0
0
0

1
1
23.315
11.739
14.456
2.5283
56.749
5.59
23.315
14.456
le-6
le-6
le-6
le-6

1
1
2.00
3.00
5.00
2.00
3.00
3.00
3.00
3.00
1
1
1
1

0
0
-0.025
-0.034
-0.003
-0.023
-0.053
-0.034
-0.045
-0.033
0
0
0
0
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Table 9: Drug-related PBPK parameters for Fentanyl and Nevirapine
Parameters
Absorotion
bioavailability
absorption rate(min-1)

85%
6.15e-3

85%
6.10e-3

Protein binding
ORM2 cone [ / / w /I]
k(ORM2) [l/(//m /L )]

6.6685
0.8532

6.6685
0.8532

Clearance
Kiax [//W Ï/min/mg protein]

3.86

0.00012

Km [//m /L ]

117

10

1
1
20
20
60
8
100
7

1
1
1
1
1
1
1
1

9
20
7

1
1
1

Partition coefficients
veins
arteries
liver
intestine
kidney
brain
lung
muscle
spleen
heart
adipose
skin

Fentanyl
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Nevirapine

APPENDIX B: SOURCE CODE
All source code can be downloaded from http://web-dev2.cs.umt.edu/~xtong/PBPKCode.
U nder G N U General Public License, you can freely use and distribute it.
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